SETD2 was associated with worse CSS in a TCGA cohort of 421 patients with primary ccRCC (p = 0.036; HR 1.68; 95% CI 1.04–2.73) [8]. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.